Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.343, WHIP COVID-19, NCT04341441 (history)
, Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.343, WHIP COVID-19, NCT04341441
HCQ prophylaxis RCT with 201 weekly HCQ patients, 197 daily HCQ patients, and 200 control patients, concluding the prophylaxis is safe. There were no grade 3 or 4 AEs, SAEs, ER visits, or hospitalizations. There was only 4 confirmed cases, 2 in the placebo arm and one in each HCQ arm. 60% of patients had exposure at baseline.HCQ 400mg weekly or HCQ 200mg daily after a loading dose of 400mg on day 1.
|
risk of symptomatic case, 2.5% lower, RR 0.98, p = 1.00, treatment 2 of 365 (0.5%), control 1 of 178 (0.6%), NNT 7219, daily and weekly HCQ combined.
|
|
risk of symptomatic case, no change, RR 1.00, p = 1.00, treatment 1 of 178 (0.6%), control 1 of 178 (0.6%), daily HCQ.
|
|
risk of symptomatic case, 4.8% lower, RR 0.95, p = 1.00, treatment 1 of 187 (0.5%), control 1 of 178 (0.6%), NNT 3698, weekly HCQ.
|
|
risk of symptomatic case, 53.3% lower, RR 0.47, p = 1.00, treatment 0 of 25 (0.0%), control 1 of 178 (0.6%), NNT 178, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), AD patients.
|
|
risk of case, 51.2% lower, RR 0.49, p = 0.60, treatment 2 of 365 (0.5%), control 2 of 178 (1.1%), NNT 174, daily and weekly HCQ combined.
|
|
risk of case, 50.0% lower, RR 0.50, p = 1.00, treatment 1 of 178 (0.6%), control 2 of 178 (1.1%), NNT 178, daily HCQ.
|
|
risk of case, 52.4% lower, RR 0.48, p = 0.61, treatment 1 of 187 (0.5%), control 2 of 178 (1.1%), NNT 170, weekly HCQ.
|
|
risk of case, 69.5% lower, RR 0.30, p = 1.00, treatment 0 of 25 (0.0%), control 2 of 178 (1.1%), NNT 89, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), AD patients.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
McKinnon et al., 23 Dec 2021, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 10 authors, trial NCT04341441 (history) (WHIP COVID-19).
Abstract: WHIP COVID-19 Study
Journal Pre-proof
Safety and Tolerability of Hydroxychloroquine in healthcare workers
and first responders for the prevention of COVID-19: WHIP
COVID-19 Study
JE McKinnon , DD Wang , M Zervos , M Saval ,
L Marshall-Nightengale , P Kilgore , P Pabla , E Szandzik ,
K Maksimowicz-McKinnon , WW O’Neill
PII:
DOI:
Reference:
S1201-9712(21)01243-1
https://doi.org/10.1016/j.ijid.2021.12.343
IJID 5900
To appear in:
International Journal of Infectious Diseases
Received date:
Revised date:
Accepted date:
30 November 2021
15 December 2021
17 December 2021
Please cite this article as: JE McKinnon , DD Wang , M Zervos , M Saval , L Marshall-Nightengale ,
P Kilgore , P Pabla , E Szandzik , K Maksimowicz-McKinnon , WW O’Neill , Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of
COVID-19: WHIP COVID-19 Study, International Journal of Infectious Diseases (2021), doi:
https://doi.org/10.1016/j.ijid.2021.12.343
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
HIGHLIGHTS
Hydroxychloroquine chemoprophylaxis is safe in high-risk populations for COVID-19
No increased cardiovascular risks with hydroxychloroquine chemoprophylaxis
Adverse events were similar between placebo and hydroxychloroquine treatment arms
Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for
the prevention of COVID-19: WHIP COVID-19 Study
Running title: WHIP COVID-19 Study
McKinnon, JE1; Wang DD2; Zervos, M1; Saval, M2; Marshall-Nightengale, L2,3; Kilgore, P1; Pabla, P4,
Szandzik, E4; Maksimowicz-McKinnon, K5; O’Neill, WW2.
1
Infectious Disease, Henry Ford Hospital, Detroit, Michigan
2
Division of Cardiovascular Disease, Center for Structural Heart, Henry Ford Hospital, Detroit,
Michigan
3
Public Health Sciences, Henry Ford Hospital, Detroit, Michigan
4
Pharmacy, Henry Ford Hospital, Detroit, Michigan
5
Rheumatology, Henry Ford Hospital, Detroit, Michigan
Address for correspondence:
John E. McKinnon, MD, MSc
Henry Ford Hospital
2799 West Grand Blvd, Clara Ford Pavilion, 432
Detroit, MI 48202
Office: 313-916-8828
Email: jmckinn3@hfhs.org
Abbreviations
AE;
Adverse Event
O
Degrees Centigrade (Celsius)
C:
CAP:
Community Acquired Pneumonia
COVID-19:
SARS-CoV-2 clinical coronavirus disease which may be diagnosed by
clinical and/or laboratory methods
CRL:
Case Report Log
DDOT:
Detroit Department of Transportation
EMR:
Electronic medical record
FDA:
U.S. Food and Drug Administration
FR:
First Responders (police, fire fighters, correctional/law officers, EMT)
HCW:
Healthcare Workers
ICF:
Informed Consent Form
IRB:
Institutional Review Board
MS:
Medical Students
NHW:
Nursing Home Workers
PI:
Principal..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.